Assessment of amphotericin b susceptibility in Leishmania infantum promastigotes by flow cytometric membrane potential assay

Cytometry

Volumn 28, Issue 2, 1997, Pages 165-169

  Azas, N ^a   Di Giorgio, C ^a   Delmas, F ^a   Gasquet, M ^a   Timon David, P ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Flow cytometry; L. infantum promastigotes; Membrane potential; Susceptibility testing

Indexed keywords

AMPHOTERICIN B;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG SENSITIVITY; FLOW CYTOMETRY; LEISHMANIA INFANTUM; MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE;

AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CARBOCYANINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; FLUORESCENT DYES; LEISHMANIA INFANTUM; MEMBRANE POTENTIALS; TIME FACTORS;

EID: 0030977274     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19970601)28:2<165::AID-CYTO10>3.0.CO;2-O     Document Type: Article

References (18)

1. Beggs WH: Physiocochemical cell damage in relation to lethal Amphotericin B action. Antimicrob Agents Chemother 38:363-364, 1994.
2. Berman J: Chemotherapy for Ieishmaniasis: Biochemical mechanisms, clinical efficacy and future strategies. Rev Infect Dis 10:560-584, 1988.
3. Bolard J: How do polyene antibiotics affect the cellular membrane properties? Biochem Biophys Acta 864:257-304, 1986.
4. Brajtburg J, Powderly W, Kobayashi G, Medoff G: Amphotericin B: Current understanding of mechanisms of action. Antimicrob Agents Chemother 34:183-188, 1990.
5. Croft S, Davidson R, Thornton EA: Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Chemother 28(Suppl. B):847-851, 1991.
6. Davidson R, Croft SL, Scott A, Maini M, Moody AH, Bryceson AD: Liposomal amphotericin B in drug resistant visceral leishmaniasis. Lancet 337:1061-1062, 1991.
7. Davidson R, Russo D: Relapse of visceral leishmaniasis in patients coinfected with Human Immunodeficiency Virus after treatment with liposomal amphotericin B. Clin Inf Dis 98:115-118, 1994.
8. Dick J, Merz G, Saral R: Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimocrob Agents Chemother 18:158-163, 1980.
9. Herwald B, Berman J: Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 46:296-306, 1992.
10. Lazanas M, Tsekes G, Papandreou S, Scandali A, Nikiforakis E: Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds. AIDS 7:1018-1019, 1991.
11. Mez W, Sandford R: Isolation and characterization of a polyene-resistant variant of Candida tropicalis. J Clin Microbiol 9:677-680, 1979.
12. Ramos H, Milhaud J, Cohen EB, Bolard J: Enhanced action of amphotericin B on Leishmania mexicana resulting from heat transformation. Antimicrob Agents Chemother 34:1584-1589, 1990.
13. Ordonez JV, Wehman NM: Amphotericin B susceptibility assay for Staphylococcus aureus. Cytometry 14:811-818, 1993
14. Ordonez JV, Wehman NM: Amphotericin B susceptibility of Candida species assessed by rapid flow cytometric membrane potential assay. Cytometry 22:154-157, 1995.
15. Pore RS: Antibiotic susceptibility testing of Candida albicans by flow cytometry. Curr Microbiol 20:323-328, 1990.
16. Shapiro H, Natale P, Kamentsky L: Estimation of membrane potentials of individual lymphocytes by flow cytometry. Proc Natl Acad Sci USA 76:5728-5730, 1979.
17. Sokol-Anderson M, Elberg S, Brajtburg J, Kobayashi G, Medoff G: Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B. Antimicrob Agents Chemother 32:702-705, 1988.
18. WHO United Nations Development Program/World Bank/World Health Organisation: Antimonials: Large-scale failure in leishmaniasis "alarming." Special program for Research and Training in Tropical Diseases. TDR News 34:1-7, 1990.